Search Result

Results for "

MTAP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (1) DNA/RNA Synthesis (1) Drug Metabolite (1) Histone Methyltransferase (15) Isotope-Labeled Compounds (2) Methionine Adenosyltransferase (MAT) (17) Phosphorylase (1) Potassium Channel (2) Pregnane X Receptor (PXR) (1) Small Interfering RNA (siRNA) (3) Somatostatin Receptor (3)
By Research Areas:	Cancer (40) Infection (1) Neurological Disease (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153390

AMG-193	Histone Methyltransferase	Cancer
AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC₅₀=0.107 μM), thereby protecting normal cells with wild-type MTAP .

HY-156680

Vopimetostat TNG-462	Histone Methyltransferase	Cancer
TNG-462 is an orally active and selective PRMT5 inhibitor with anti-tumor activity against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation cancers .

HY-148419

Ralometostat 2 Publications Verification TNG908	Histone Methyltransferase	Cancer
TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research .

HY-101496

MT-DADMe-ImmA 4 Publications Verification MTDIA; Methylthio-DADMe-Immucillin A	Histone Methyltransferase	Cancer
MT-DADMe-ImmA is an inhibitor of human 5'-methylthioadenosine phosphorylase (MTAP) with a K_i of 90 pM.

HY-112130

AGI-24512 2 Publications Verification	Methionine Adenosyltransferase (MAT)	Cancer
AGI-24512 is a potent methionine adenosyltransferase 2α (MAT2A) inhibitor, with an IC₅₀ of 8 nM. AGI-24512 triggers DNA damage response. AGI-24512 can block proliferation of MTAP-deleted cancer cells in vitro. AGI-24512 can be used for researching anticancer .

HY-16933

L-Alanosine 1 Publications Verification NSC-153353; SDX-102	Antibiotic DNA/RNA Synthesis	Infection Cancer
L-Alanosine (NSC-153353), an antibiotic from Streptomyces alanosinicus, has antineoplastic activity. L-Alanosine (NSC-153353) inhibits adenylosuccinate synthetase, which converts inosine monophospate (IMP) into adenylosuccinate. L-Alanosine is the inhibitor for methylthioadenosine phosphorylase (MTAP) .

HY-138684

MRTX9768	Histone Methyltransferase	Cancer
MRTX9768 is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .

HY-162353

AZ'9567		Cancer
AZ'9567 is an orally active MAT2a inhibitor with a pIC₅₀ of 9.1. AZ'9567 binds to MAT2a allosterically, reduces the synthesis of SAM, decreases SDMA levels, and exerts antiproliferative effects on *MTAP*-knockout cells. AZ'9567 depletes SAM, causes methionine accumulation in plasma and tissues, triggers adaptive disorders in one-carbon metabolism, transsulfuration metabolism and lipid metabolism, and induces oxidative stress, hepatic steatosis and lipid homeostasis imbalance. AZ'9567 can be used in studies related to MTAP-deficient/deleted cancers .

HY-145777

AGI-43192	Methionine Adenosyltransferase (MAT)	Neurological Disease Cancer
AGI-43192 is a potent and orally active inhibitor of methionine adenosyltransferase 2A (MAT2A) that limitedly penetrates the blood-brain barrier. AGI-43192 exhibits inhibitory activitity against MAT2A and S-adenosyl methionine (SAM) in HCT-116 MTAP-null cells with IC₅₀s of 32 and 14 nM. AGI-43192 can significantly inhibit the proliferation of HCT-116 cells and tumor growth. AGI-43192 can be used to study the role of SAM regulation in the central nervous system (CNS) and colon cancer .

HY-145778

AGI-41998	Methionine Adenosyltransferase (MAT)	Neurological Disease Cancer
AGI-41998 is a potent and orally active inhibitor of methionine adenosyltransferase 2A (MAT2A) that effectively penetrates the blood-brain barrier. AGI-41998 exhibits inhibitory activities against MAT2A and S-adenosyl methionine (SAM) in HCT-116 MTAP-null cells with IC₅₀s of 22 nM and 34 nM. AGI-41998 can significantly inhibit the proliferation of HCT-116 cells and tumor growth. AGI-41998 can be used to study the role of SAM regulation in the central nervous system (CNS) and colon cancer .

HY-162783

AZ-PRMT5i-1	Histone Methyltransferase	Cancer
AZ-PRMT5i-1 (Compound 28) is an effective and orally active MTAP-selective PRMT5 inhibitor. AZ-PRMT5i-1 also demonstrates MTA cooperativity and exhibits both in vitro and in vivo antitumor activities, and can be used to study MTAP-deficient cancers .

HY-162010

MAT2A-IN-13	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile. MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors research .

HY-112129

AGI25696-analog Desmethyl AGI25696	Methionine Adenosyltransferase (MAT)	Cancer
AGI-25696 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.

HY-174983

PRMT5-MTA-IN-6	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-6 (Compound 31) is a selective MTA-cooperative PRMT5 inhibitor. PRMT5-MTA-IN-6 exhibits potent inhibitory activity against PRMT5・MTA (IC₅₀: 6.6 nM). PRMT5-MTA-IN-6 selectively inhibits the growth of MTAP-deleted HCT-116 cells (IC₅₀: 319 nM). PRMT5-MTA-IN-6 can be used in the research of MTAP-deleted tumors .

HY-176702

PRMT5-MTA-IN-5	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-5 (Compound 7) is an orally active, irreversible PRMT5-MTA complex (PRMT5•MTA) inhibitor (IC₅₀=1.15 nM). PRMT5-MTA-IN-5 blocks arginine methylation and inhibits ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-5 potently inhibits proliferation in MTAP-deficient tumor cells. PRMT5-MTA-IN-5 is promising for research of MTAP-deficient solid tumors, such as liver, breast, and pancreatic cancers .

HY-RS16680

Mtap Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mtap Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mtap gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mtap Mouse Pre-designed siRNA Set A Mtap Mouse Pre-designed siRNA Set A

HY-RS23115

Mtap Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Mtap Rat Pre-designed siRNA Set A contains three designed siRNAs for Mtap gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mtap Rat Pre-designed siRNA Set A Mtap Rat Pre-designed siRNA Set A

HY-RS08749

MTAP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MTAP Human Pre-designed siRNA Set A contains three designed siRNAs for MTAP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MTAP Human Pre-designed siRNA Set A MTAP Human Pre-designed siRNA Set A

HY-W750643

m-APTA 5′-S-(3-Aminophenyl)-5′-thioadenosine	Phosphorylase	Cancer
m-APTA (5'-S-(3-aminophenyl)-5'-thioadenosine) is a selective chemoprotective agent targeting methylthioadenosine phosphorylase (MTAP). m-APTA can be converted into adenine, which is a crucial step in protecting normal cells from the toxicity of nucleobase analogues (NBA). m-APTA is promising for research of MTAP-deficient cancers .

HY-155149

MAT2A-IN-12	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A Allosteric inhibitor 2 is a potent and selective MAT2A allosteric inhibitor with an IC₅₀ of 5 nM. MAT2A Allosteric inhibitor 2 shows nanomolar activity (IC₅₀=5 μM) in the the proliferation assay (MTAP ^-/- cell line) .

HY-170906S

MAT2A-IN-23	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

HY-173281

MAT2A-IN-24	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-24 (Compound 9) is an inhibitor of methionine adenosyltransferase 2a (MAT2a). The IC₅₀ value for the inhibition of MAT2a is 20 nM, and the IC₅₀ value for the antiproliferative activity against HAP1MTAP–/– cells is 10 nM. MAT2A-IN-24 can be used in the research field of tumor diseases associated with MTAP deficiency .

HY-153390A

(R)-AMG-193	Histone Methyltransferase	Cancer
(R)-AMG-193 is an isomer of AMG 193 (HY-153390). AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC₅₀=0.107 μM), thereby protecting normal cells with wild-type MTAP .

HY-170421

MAT2A-IN-16	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-16 is a MAT2A inhibitor and inhibits cell proliferation of MTAP ^-/- HCT-116 cells (IC₅₀: 20 nM) .

HY-172733

PRMT5-MTA-IN-3	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective protein arginine methyltransferase 5 (PRMT5) inhibitor. PRMT5-MTA-IN-3 inhibits cell proliferation in the MTAP-deficient colorectal cancer HCT - 116 cell line with an IC₅₀ value of 5 nM. PRMT5-MTA-IN-3 is promising for research of cancers, especially for MTAP-deficient tumors, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer .

HY-172733S

PRMT5-MTA-IN-3-d3	Isotope-Labeled Compounds Histone Methyltransferase	Cancer
PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

HY-168445

MAT2A-IN-21	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-21 (compound 28) is a potent methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC₅₀ of 49 nM. MAT2A-IN-21 selectivity inhibits MTAP-deficient cancer cells .

HY-170905S

MAT2A-IN-22	Methionine Adenosyltransferase (MAT) Isotope-Labeled Compounds	Cancer
MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active MAT2A inhibitor with an IC₅₀ of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects .

HY-138684A

MRTX9768 hydrochloride	Histone Methyltransferase	Cancer
MRTX9768 hydrochloride is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .

HY-144184

MAT2A-IN-6	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .

HY-144185

MAT2A-IN-7	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .

HY-144181

MAT2A-IN-5	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .

HY-142929

MAT2A-IN-2	Somatostatin Receptor	Cancer
MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .

HY-142928

MAT2A-IN-1	Somatostatin Receptor	Cancer
MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .

HY-142930

MAT2A-IN-3	Somatostatin Receptor	Cancer
MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .

HY-163799

PRMT5-MTA-IN-1	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-1 (Compound A9a) is an inhibitor for protein arginine methyltransferase PRMT5-MTA. PRMT5-MTA-IN-1 inhibits the proliferation of colorectal cancer cell HCT116 wildtype and MTAP del mutant, with an IC₅₀ of 16 nM and 2.47 μM. PRMT5-MTA-IN-1 exhibits good liver microsomal stability and film permeability. PRMT5-MTA-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mice .

HY-183568

MAT2A-IN-26	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-26 is an orally active MAT2A inhibitor with a human IC₅₀ of 17.53 nM. MAT2A-IN-26 inhibits the enzymatic activity of MAT2A, thereby reducing the levels of S-adenosylmethionine (SAM) and symmetric dimethylarginine (sDMA). MAT2A-IN-26 inhibits the proliferation of MTAP-deficient cancer cells and induces anti-tumor efficacy in xenograft models. MAT2A-IN-26 can be used in non-small cell lung cancer research .

HY-179622

ZS34	Methionine Adenosyltransferase (MAT)	Cancer
ZS34 is a potent, orally active, and selective MAT2A inhibitor with an IC₅₀ of 13.7 nM, displaying minimal hERG and UGT1A1 liabilities. ZS34 selectively suppresses the growth of methylthioadenosine phosphorylase (MTAP)-deficient cancer cells by inhibiting SAM synthesis, reducing SDMA levels, and inducing DNA damage. ZS34 exhibits antitumor efficacy in a HCT116 MTAP ^-/- xenograft mouse model. ZS34 can be used for the research of MTAP-deficient cancer .

HY-182400

AGI-25696	Methionine Adenosyltransferase (MAT)	Cancer
AGI-25696 is an orally active ethionine adenosyltransferase 2A (MAT2A) inhibitor with an IC₅₀ of 97 nM. AGI-25696 reduces intracellular SAM levels in cancer cells. AGI-25696 inhibits tumor growth in mice bearing subcutaneous KP4 MTAP-null pancreatic xenografts. AGI-25696 can be used for the research of mtap-deleted pancreatic cancer .

HY-180918

ERG-IN-4	Potassium Channel Pregnane X Receptor (PXR)	Cancer
ERG-IN-4 (Compound 12) is an orally active, selective ERG inhibitor with an IC₅₀ of 5.2 μM for hERG. ERG-IN-4 activates PXR. ERG-IN-4 exhibits anticancer activity against MTAP-deleted non-small cell lung cancer .

HY-180919

ERG-IN-5	Potassium Channel Drug Metabolite	Cancer
ERG-IN-5 (Compound M1) is a metabolite of ERG-IN-4 (HY-180918), and it is a hERG potassium channel inhibitor with an IC₅₀ of 1.5 μM. ERG-IN-5 is cytotoxic to MTAP ^del HCT116 and its CC₅₀ is 28 nM. ERG-IN-5 can be used for the study of colon cancer .

HY-180816

PRMT5-MTA-IN-7	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-7 (Compound 14) is a selective PRMT5-MTA inhibitor. PRMT5-MTA-IN-7 exhibits K_D values of PRMT5-MTA-IN-7 for PRMT5-MTA and PRMT5-SAM of 236 nM and 2.84 μM respectively, and the IC₅₀ values of 4.08 and 13.6 μM respectively. PRMT5-MTA-IN-7 can selectively inhibit the proliferation of MTAP-deficient cancer cells. PRMT5-MTA-IN-7 can be used for the study of colon cancer .

HY-181260

PRMT5-MTA-IN-8	Histone Methyltransferase Apoptosis	Cancer
PRMT5-MTA-IN-8 is an orally active PRMT5-MTA complex inhibitor (IC₅₀ = 4.4 nM). PRMT5-MTA-IN-8 inhibits the intracellular production of symmetric dimethylarginine (SDMA) as well as the proliferation of MTAP-deficient cells. PRMT5-MTA-IN-8 exerts antitumor efficacy by inhibiting PRMT5, reducing SDMA levels and inducing tumor cell apoptosis in mouse models of triple-negative breast cancer. PRMT5-MTA-IN-8 can be used in research related to cancers such as triple-negative breast cancer .

Cat. No.	Product Name	Chemical Structure

HY-170906S

MAT2A-IN-23
MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

MAT2A-IN-23

MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

HY-172733S

PRMT5-MTA-IN-3-d3
PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

PRMT5-MTA-IN-3-d3

PRMT5-MTA-IN-3-d₃ (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d₃ is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d₃ has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC₅₀ values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d₃ has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .

HY-170905S

MAT2A-IN-22
MAT2A-IN-22 (Compound 29-1) is a BBB-penetrable and orally active MAT2A inhibitor with an IC₅₀ of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects .

Host:	Rabbit (3)
Reactivity:	Human (3) Mouse (3)
Application:	IHC-P (1) ICC/IF (1) IF-Tissue (1) IP (1) IHC-F (1) WB (3) FC (1)
Isotype:	IgG (3)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2) Recombinant (2)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87602

	MTAP Antibody (YA7286)	WB, IHC-P, IHC-F, IF-Tissue, FC, ICC/IF, IP	Human, Mouse
	MTAP Antibody (YA7286) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MTAP.

HY-P83340

	MTAP Antibody (YA3085) BDMF; MSAP; DMSFH; LGMBF; DMSMFH; c86fus; HEL-249	WB	Human, Mouse
	MTAP Antibody (YA3085) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MTAP.

HY-P83340A

	MTAP Antibody (YA3085)(PBS only) BDMF; MSAP; DMSFH; LGMBF; DMSMFH; c86fus; HEL-249	WB	Human, Mouse
	MTAP Antibody (YA3085) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MTAP.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: